{"id":126883,"date":"2018-11-20T21:40:14","date_gmt":"2018-11-20T21:40:14","guid":{"rendered":"http:\/\/www.georgianewsdesk.com\/news\/story\/126883\/creative-biolabs-develops-ipatasertiblinker-complexes-for-antibodydrug-conjugates.html"},"modified":"2018-11-20T21:40:14","modified_gmt":"2018-11-20T21:40:14","slug":"creative-biolabs-develops-ipatasertiblinker-complexes-for-antibodydrug-conjugates","status":"publish","type":"post","link":"http:\/\/www.honolulunewsnow.com\/news\/story\/126883\/creative-biolabs-develops-ipatasertiblinker-complexes-for-antibodydrug-conjugates.html","title":{"rendered":"Creative Biolabs Develops Ipatasertib-linker Complexes for Antibody-drug Conjugates"},"content":{"rendered":"
New York, November 20th, 2018 Based on the exclusive \u201cDrugLnk\u201d organic synthesis platform, Creative Biolabs develops Ipatasertib linker complexes using readily available or customized linkers for antibody conjugation in a timely and cost-effective manner.<\/div>\n

New York, November <\/strong>20<\/strong>th, 2018  <\/strong>Based on the exclusive “DrugLnk” organic synthesis platform, Creative Biolabs develops Ipatasertib<\/a> linker complexes using readily available or customized linkers for antibody conjugation in a timely and cost-effective manner.<\/p>\n

As a regulator for a number of biological processes, Akt is a serine\/threonine-specific protein kinase that plays a key role in the PI3K\/Akt pathway. The activated Akt is capable of contributing to tumor anti-apoptotic activities and regulating cell cycle progression. Ipatasertib, also known as GDC-0068, is a strong ATP-competitive pan-AKT inhibitor, which shows a powerful inhibition of all protein kinase B (Akt) isoforms but a weak suppression towards other members of the protein kinase family. For the treatment of both tumor xenograft mouse models and human cancer cell lines, ipatasertib showed a significant suppression of Akt signaling, bringing a disruption in cell cycle progression and reduced cancer cell viability.<\/p>\n

“As a highly selective and specific Akt inhibitor<\/a>, ipatasertib not only exhibits dose-dependent inhibition of Akt signaling and potent antitumor activity, but also shows distinguished level of activities in cells with and without activated Akt signaling, making it an excellent choice as a new anti-cancer therapeutic agent” Said an expert in Creative Biolabs.<\/p>\n

“Composed of cytotoxic agents conjugated to monoclonal antibodies, antibody-drug conjugates (ADCs) can target antigens differentially overexpressed on tumor cells. Due to its potent cytotoxicity, ipatasertib is considered to be a promising cytotoxic payload for the construction of ADCs. Our team can provide tailored strategies for antibody-drug conjugates (ADCs) and other targeted antibody therapeutics development by ipatasertib (GDC-0068) and derivatives as payloads to treat a wide range of tumor models and cancer cell lines.”<\/p>\n

With rich experience and an advanced platform, Creative Biolabs can customize numerous cytotoxic agents for ADC engineering<\/a> to meet a variety of specific needs of both industrial and academic clients. Meanwhile, other tailored services related to antibody-drug conjugate development are also available in Creative Biolabs owing to its one-stop ADC development platform.<\/p>\n

About Creative Biolabs<\/p>\n

Creative Biolabs has established our leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. We offer our customers with comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production\/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation. Furthermore, our inventory also contains an extensive list of linkers, payloads, payload-linker sets, and commonly used ADCs for quick deployment and concept validation.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative Biolabs<\/a>
Contact Person:<\/strong> Bella Smith
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.creative-biolabs.com\/adc\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

New York, November 20th, 2018 Based on the exclusive \u201cDrugLnk\u201d organic synthesis platform, Creative Biolabs develops Ipatasertib linker complexes using readily available or customized linkers for antibody conjugation in a<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts\/126883"}],"collection":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/comments?post=126883"}],"version-history":[{"count":0,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts\/126883\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/media?parent=126883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/categories?post=126883"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/tags?post=126883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}